5-substituted 7- [4-(2-pyridyl)phenylmethylamino] -3-isopropylpyrazolo4,3-D]pyrimidine derivatives, use thereof as medicaments, and pharmaceutical compositions

5-Substituted 7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidine of general formula I

• wherein,
• R is selected from the group containing
• heterocycloalkyl, which is a C3-C10 cycloalkyl group wherein one or more, of the ring carbons is/are replaced with a heteroatom selected from N, O, S, said heterocycloalkyl group being optionally substituted independently at each occurrence by at least one substituent selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl, and amino substituents;
• heterocycloalkyl alkyl, which is a C3-C10 cycloalkyl group wherein one or more, of the ring carbons is/are replaced with a heteroatom selected from N, O, S, bound via a C1-C4 alkylene spacer, said heterocycloalkyl alkyl group being optionally substituted independently at each occurrence by at least one substituent selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl and amino substituents;
• R′—X
• wherein X is selected from —NH— and —N(C1-C8 alkyl)-moiety, and
• R′ is selected from
• C2-C10 linear or branched alkyl, optionally substituted by at least one substituent selected from hydroxy and amino substituents;
• (dialkylamino)alkyl group wherein the alkyls are independently selected from C1-C10 linear or branched alkyl;
• C3-C10 cycloalkyl, which is a cyclic or polycyclic alkyl group containing 3 to 10 carbon atoms, optionally substituted independently at each occurrence by at least one substituent selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl and amino substituents;
• heterocycloalkyl, which is a C3-C10 cycloalkyl group wherein one or more, of the ring carbons is/are replaced with a heteroatom selected from N, O, S, said heterocycloalkyl group being optionally substituted independently at each occurrence by at least one substituent selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl and amino substituents;
• heterocycloalkyl alkyl, which is a C3-C10 cycloalkyl group wherein one or more, of the ring carbons is/are replaced with a heteroatom selected from N, O, S, bound via a C1-C4 alkylene spacer, said heterocycloalkyl alkyl group being optionally substituted independently at each occurrence by at least one substituent selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl and amino substituents;
• benzyl group, optionally substituted independently at each occurrence by at least one substituent selected from the group consisting of fluoro, chloro, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl and amino substituents;
• and pharmaceutically acceptable salts thereof, or addition salts with acids.